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Abstract
One of the challenging problems in the etiology of diseases is to explore the relationships between initiation and
progression of diseases and abnormalities in local regions of metabolic pathways. To gain insight into such relationships, we
applied the ‘‘k-clique’’ subpathway identification method to all disease-related gene sets. For each disease, the disease risk
regions of metabolic pathways were then identified and considered as subpathways associated with the disease. We finally
built a disease-metabolic subpathway network (DMSPN). Through analyses based on network biology, we found that a few
subpathways, such as that of cytochrome P450, were highly connected with many diseases, and most belonged to
fundamental metabolisms, suggesting that abnormalities of fundamental metabolic processes tend to cause more types of
diseases. According to the categories of diseases and subpathways, we tested the clustering phenomenon of diseases and
metabolic subpathways in the DMSPN. The results showed that both disease nodes and subpathway nodes displayed slight
clustering phenomenon. We also tested correlations between network topology and genes within disease-related metabolic
subpathways, and found that within a disease-related subpathway in the DMSPN, the ratio of disease genes and the ratio of
tissue-specific genes significantly increased as the number of diseases caused by the subpathway increased. Surprisingly,
the ratio of essential genes significantly decreased and the ratio of housekeeping genes remained relatively unchanged.
Furthermore, the coexpression levels between disease genes and other types of genes were calculated for each subpathway
in the DMSPN. The results indicated that those genes intensely influenced by disease genes, including essential genes and
tissue-specific genes, might be significantly associated with the disease diversity of subpathways, suggesting that different
kinds of genes within a disease-related subpathway may play significantly differential roles on the diversity of diseases
caused by the corresponding subpathway.
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Introduction
Genes/proteins rarely function in isolation in and outside the cell,
but interact with each other to form complex cellular pathways of
metabolic, regulatory, or protein complexes to perform biological
functions [1,2,3,4]. The initiation and progression of diseases are
highly associated with abnormalities in the biological functions of
pathways. Especially, abnormalities in local regions (that is,
subpathways) of cellular pathways contributes to the etiology of
diseases [5,6,7,8]. Among the cellular pathways, metabolic pathways
are at the heart of the celland areamongmostchallenging biological
networks and, arguably, the ones with most potential for immediate
applicability [4,5,6]. Therefore, to elucidate the intricate relation-
ships between human diseases and the disruption of underlying
functional regions in metabolic pathways is an important challenge
in the field of biology and medicine [5,9,10].
However, it is a challenge to identify disease-related regions of
metabolic pathways. Some studies have successfully identified
disease risk metabolic subpathways from low-throughput biolog-
ical experimental studies. For example, an abnormality in
norepinephrine metabolism, which is a sub-pathway of the
‘tyrosine metabolism’ pathway, was found to be associated with
the initiation and progression of some diseases, such as cancer,
and neurological, psychiatric, endocrine and cardiovascular
diseases [8,11]. If all disease-related subpathways can be
identified by biological studies, the global relationships between
metabolic subpathways and diseases could be constructed and
studied in-depth from the viewpoint of network biology [3],
which would can give global clues to possible metabolism-related
treatment of diseases [3,12,13,14,15]. However, currently, it is
difficult to construct the global relationships between metabolic
subpathways and a variety of diseases via low-throughput
biological experimental studies. Although disease-related genes
can be identified effectively by a variety of methods [16,17], the
identification of disease-related metabolic subpathways is very
difficult in terms of the lack of high-throughput experimental
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21131technology. High-throughput reactome arrays for the functional
analysis of metabolic pathways were recently developed but have
still not been applied to the identification of human disease-
related subpathways [18].
Currently, the pathway-enriched methods are an efficient
alterative strategy for establishing disease-pathway relationships
by identifying disease risk pathways based on disease-related genes
[8,14,19,20,21,22,23]. Information on disease-related genes, such
as that available from the Genetic Association Database (GAD)
[24] has become increasingly available for constructing high-
quality disease–metabolic pathway relationships. Furthermore, the
high quality pathway structure data available from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [25] is invaluable
for identifying the disease risk regions of pathways. Here, we
constructed a global disease–metabolic subpathway network
(DMSPN) in which nodes represent diseases or metabolic
subpathways and these were connected by an edge if genes
related to a particular disease were significantly enriched to the
subpathway. We applied the ‘‘k-clique’’ pathway identification
method to all disease-related gene sets. For each disease, the
disease risk local regions of metabolic pathways were finally
identified using disease genes and pathway structure data. These
regions were considered as subpathways associated with the
disease. We then used the methods of network biology to analyze
global relationships between diseases and metabolic subpathways
based on the basic properties of the DMSPN, the clustering
phenomenon for disease nodes and subpathway nodes, the
correlations between network topology and genes within disease-
related metabolic subpathways. Through these analyses, our
findings offer insight into the interplay between metabolic
subpathways and human diseases.
Results
Construction of the disease–metabolic subpathway
network
We constructed a disease–metabolic subpathway network based
on disease genes and pathway structure data (Figure 1). First, we
downloaded all terms of gene-disease associations (N=39910) in the
GAD (December 15, 2008). After some necessary dealing steps such
as merging redundant terms and converting gene identifiers (see
Text S1 and Dataset S1), 15149 unique gene–disease associations
were finally obtained from 39910 primary terms. The 15149 gene–
disease associations were composed of 412 diseases, which are
naturally grouped by the GAD into 18 disease classes, and 2831
disease genes (see Dataset S2). Second, for each disease among the
412 diseases, we identified the disease-related subpathway based on
the corresponding gene sets. We used the ‘‘k-cliques’’ subpathway
identification method provided by the SubpathwayMiner software
package [8] to identify statistically significantly enriched subpath-
ways with a P-value,0.01 (see Text S1). This method is able to
identify subpathways with a given distance parameter k, which
means that the distance among all enzymes within the subpathways
isnogreaterthank[8].Briefly,eachmetabolic pathwayisconverted
to an undirected graph with enzymes as nodes. After inputting the
given disease-related genes and distance parameter k, the method
can mine each metabolic subpathway and then identify statistically
significantly enriched subpathways. In this study, we mainly discuss
the DMSPN with k=3. This parameter setting ensures that the
identified disease risk subpathways are located in the disease-related
local regions of pathways. When k=3, a total of 743 metabolic
subpathways were generated, of which 302 were significantly
associated with 243 of the 412 diseases. These subpathways and
diseases generated 4288 significant disease–metabolic subpathway
associations. Finally, we combined these disease–metabolic sub-
pathway associations to construct the DMSPN with k=3 (see
Dataset S3). The network was a bipartite network consisting of two
disjointed sets of nodes. One set corresponded to 243 diseases, and
the other set corresponded to 302 disease-related metabolic
subpathways (circular nodes represent diseases and rectangular
nodes represent subpathways in Figure 2). A disease and a
subpathway were connected if the corresponding disease-related
genes were significantly enriched to the corresponding subpathway.
We also developed a platform for constructing disease–metabolic
subpathway networks (Figure S1), which was integrated into the
SubpathwayMiner package freely available at http://cran.r-project.
org/web/packages/SubpathwayMiner/. Using this platform, we
constructed disease–metabolic subpathway networks based on the
different scales of subpathways.
The basic network features of the DMSPN
The DMSPN with k=3 was composed of 545 nodes (302
subpathways and 243 diseases), and 4288 edges (Figure 2). The
edges in the DMSPN were denser than expected by chance with P-
values,0.001 (seeTextS1and FigureS2C), and most nodesformed
a giant connected component, suggesting that the diseases and
metabolic subpathways were much closely connected at the system
level. The degree of subpathway nodes as well as that of disease
nodes (circular and rectangular nodes of different sizes in Figure 2)
had fat tails (Figure 3). On average, a subpathway in the DMSPN
was associated with 14 diseases, and the initiation and progression of
a disease involved 20 subpathways. The degree distribution of
subpathway nodes was much broader than that of disease nodes. To
further test the differences between the degree distribution of the
subpathway and disease nodes, we generated 1000 random
networks and compared them with the actual DMSPN (see Text
S1). We found that the degree distribution of the subpathway nodes
of the actual DMSPN was significantly broader than that of the
randomnetworks(P-value,10e–10,see SIFigure S2A),whereasthe
distribution of disease nodes did not display such a highly significant
difference (P-value=0.02, see SI Figure S2B), suggesting that the
different subpathways in the DMSPN possessed the considerable
differences with respect to causing diseases. On the one hand, few
metabolicsubpathwayswerelinkedtomanydiseases.Thedegreesof
only 20 subpathways (nodes with degree.80 in Figure 3A, and
ellipse I region at the central top part of Figure 2) among the 302
total subpathways were significantly higher than the degrees of other
subpathways. Interestingly, most of these connected subpathways
were involved with lipid metabolism (9/20) (red rectangular nodes)
and amino acid metabolism (7/20) (orchid rectangular nodes),
suggesting that abnormalities in fundamental metabolism may tend
to cause more types of disease. For example, for lipid metabolism,
five of the nine subpathways were involved with arachidonic acid
metabolism. Some studies showed that arachidonic acid could
generate many compounds with different cellular or extracellular
tissue and organ targets, causing a wide range of clinical effects [26].
Arachidonic acid metabolism has been reported to be associated
with different kinds of diseases, including inflammation, hyperten-
sion, diabetes, cardiovascular diseases, depression, schizophrenia,
Alzheimer’s disease and cancer [27]. Of seven amino acid
metabolism subpathways, five subpathways belonged to tryptophan
metabolism. The dysfunction of tryptophan metabolism has been
found to be associated with many diseases including cancer, and
psychological, immune and cardiovascular diseases [28,29,30,31].
Of the other 4 of the 20 subpathways with degree.80, the
subpathways path:00980_1 and path:00361_1 with degrees of 122
and 105, respectively, belonged to metabolism of xenobiotics by
cytochrome P450 and gamma-hexachlorocyclohexane degradation,
Disease-Metabolic Subpathway Network
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metabolism. Cytochrome P450 is involved in the bioactivation
and detoxification of a variety of xenobiotics [32]. Abnormal
metabolism of xenobiotics by P450 may cause inborn errors in
metabolism and contribute to many clinically relevant diseases [33].
The subpathways path:00232_1 and path:00232_2 (light green
rectangular nodes) belonged to caffeine metabolism, were associated
with 98 diseases in the DMSPN and had been proved to be
potentially related to many diseases including Alzheimer’s disease,
asthma, cancer, diabetes and Parkinson’s disease [34]. On the other
hand, many metabolic subpathways were connected to only a few
diseases in the DMSPN. For example, path:00072_1, path:00512_1
andpath:00631_1wereonlyconnectedtoonedisease.The synthesis
and degradation pathway of ketone bodies (path:00072_1), which
belonged to a subpathway of lipid metabolism, was only associated
with lipid-related diseases (ellipse II in Figure 2). Similarly, the O-
glycan biosynthesis subpathway (path:00512_1) was only linked to
IgA-nephropathy in the DMSPN (ellipse III) [35], and the 1,2-
dichloroethane degradation subpathway (path:00631_1), which was
found to be associated with the initiation and progression of cancer
[36], was only linked to laryngeal cancer (ellipse IV).
Although the degree distribution of disease nodes was no
broader than that of the subpathway nodes, the degree of diseases
also spanned a wide range from 1 to 100 (Figure 3B, and circular
nodes of different sizes in Figure 2). Diseases with high degrees
displayed significantly different characteristics compared with
diseases with low degrees. Most diseases with high degrees were
well-known, highly heterogeneous, complex diseases such as
Parkinson’s disease (ellipse V), hypertension (ellipse VI), Alzhei-
mer’s disease (ellipse VI) and some cancers (the central part of
Figure 1. Schematic of the construction of the disease–metabolic subpathway network (DMSPN). We constructed a DMSPN based on
disease genes and pathway structure data. First, we obtained 15149 unique gene–disease associations after processing all terms of gene–disease
associations in the Genetic Association Database (GAD). Second, for each disease, we used the ‘‘k-cliques’’ subpathway identification method to
identify statistically significantly enriched subpathways with P-value,0.01, to generate disease–metabolic subpathway associations for each disease.
Finally, we combined these disease–metabolic subpathway associations to form the DMSPN.
doi:10.1371/journal.pone.0021131.g001
Disease-Metabolic Subpathway Network
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21131Figure 2. The DMSPN is a bipartite network. The circles and rectangles in the network correspond to diseases and metabolic subpathways
respectively. A disease and a subpathway are connected by an edge if the set of disease genes are statistically significantly enriched to the
corresponding subpathway. Node size is proportional to the degree of the node. Nodes are colored according to their categories, which include 18
disease classes from the Genetic Association Database (GAD) for disease nodes and 11 subpathway classes from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway database for metabolic subpathway nodes. Edges are colored according to the enrichment significance (P-values) of
associations between diseases and subpathways.
doi:10.1371/journal.pone.0021131.g002
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usually only associated with a few subpathways. Interestingly,
many diseases with low degrees, including Addison’s disease
(ellipse VII) and Graves’ disease (ellipse VII), belonged to
autoimmune diseases (khaki circular nodes at the lower right part
of Figure 2). Autoimmune diseases occur when the body’s immune
system attacks its own special tissues or systems, thinking they are
foreign threats. Therefore, the initiation and progression of these
diseases are usually pathway-specific. For example, Addison’s
disease, which was only associated with the subpathway
path:00100_3 (a subpathway of the steroid biosynthesis pathway)
in the DMSPN, is mainly caused by impaired steroidogenesis [37].
Evaluating the clustering phenomenon of diseases and
subpathways
As illustrated in Figure 2, diseases were divided into 18 classes
(circular nodes of different colors) according to the GAD, and
subpathways were divided into 11 classes (rectangular nodes of
different colors) according to the KEGG. If a subpathway node
has a high degree, the subpathway is associated with the initiation
and progression of more diseases. However, we questioned
whether these potential diseases induced by the subpathway
belong to more different disease classes. To test this, we calculated
the disease diversity of each subpathway in the DMSPN. Disease
diversity of a subpathway is defined as the unique class numbers of
diseases associated with the subpathway divided by the total
numbers of disease classes. We found that there was a significant
positive correlation between disease diversity and degree of a
subpathway (P-value,2.2e–16, see SI Figure S3), suggesting that
the higher the subpathway degree, the more types of disease are
caused by disruption of the subpathway.
Some studies have shown that diseases within the same disease
class tend to be clustered into densely connected groups in disease
networks [12,14,38,39]. To probe whether functional clustering of
DMSPN exists, we calculated the (BD, BH) values of each class to
test the clustering phenomenon of disease classes and subpathway
classes in the DMSPN respectively (see Materials and methods).
Briefly, for a disease class, BD.1 (BD,1) indicates that diseases in
the disease class tend to connect more (less) densely among
themselves than the random expectation. BH.1 (BH,1) means
that diseases in the disease class have more (fewer) connections to
diseases in other classes than the random expectation. If BD.BH,
diseases in the disease class tend to display a clustering
phenomenon in the DMSPN. If BD.1 and BH,1, diseases in
the disease class tend to display a clear clustering phenomenon in
the DMSPN. Similarly, we can also calculate the BD and BH
values of subpathways in a subpathway class. The results showed
that for disease classes, the average values of (BD, BH) were 4.4
and 2.3 respectively (Figure 4A). The average value of BD was one
times more than that of BH, suggesting that diseases in the same
disease class tend to connect more densely than expected by
chance. However, these diseases still connected densely with
diseases in other disease classes as demonstrated by their high BH
value (BH.1). For example, the BD value of ‘‘pharmacogenomic’’
class was 3 times more than the BH value that was equal to 2.5
(Figure 4A), suggesting that diseases in the class have more similar
mechanism of happen, but have still similar mechanism of happen
with some diseases in other disease classes. Therefore, diseases in
the same disease class displayed a slight clustering tendency.
However, for several disease classes, including the aging disease
class and the cardiovascular disease class, the BD values were
similar to the BH values. For subpathway classes, the average
values of BD and BH were 2.8 and 1.2 respectively (Figure 4B).
The average value of BD was one times more than that of BH,
suggesting that subpathways in the same subpathway class display
a slight clustering tendency. For example, fluorene degradation
(BD=4.7, BH=1.4), nucleotide metabolism (BD=2.2, BH=0.9)
and glycan biosynthesis (BD=2.6, BH=0.9) displayed a slight
Figure 3. Mapping between diseases and subpathways. (A) Distribution of the number of mapped diseases per subpathway. (B) Distribution
of the number of mapped subpathways per disease.
doi:10.1371/journal.pone.0021131.g003
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of these subpathways tends to cause similar diseases. However,
carbohydrate metabolism (BD=1.0, BH=1.1) and amino acid
metabolism (BD=1.9, BH=1.0) displayed low value.
The (BD, BH) measure evaluated clustering tendency for a
given class and showed that diseases (and subpathways) in the
same disease (and subpathway) class displayed a slight clustering
tendency. After clustering the nodes in the DMSPN, without
considering disease class information, diseases in the same clusters
should tend to belong to the same disease class. To detect this, we
performed hierarchical clustering [40,41] on the DMSPN
(Figure 5A). The results showed that diseases belonging to the
same disease class tend to group together. However, this does not
mean that all diseases in the same disease class were perfectly
clustered. In fact, diseases in the same class tend to be clustered at
the local level, but not at the global level (e.g., the neurological and
psychological diseases (dark and light green labels in Figure 5C)).
That is, diseases in the same disease class tended to form many
small clusters instead of individual large clusters. This phenom-
enon was also interpreted by the high BD and BH values of the
disease class described above, because the high BH value indicates
that some diseases in a disease class are closely related to diseases
in other classes. Next, we questioned what factors contribute to the
high degree of similarity between diseases belonging to different
disease classes. One factor may be the degree of genetic similarity
in a disease class. Then, what contribute to the high similarity of
diseases belonging to different disease classes? For example, the
neurological and psychological diseases have similar genetic
origins and their genetic similarity of them may make the two
kinds of diseases merge into one large cluster when clustering them
(dark and light green labels in Figure 5C). Another factor may be
different viewpoints with regard to classifying a disease, which
divide some the co-characteristic diseases into different disease
classes and cause the ambiguous boundaries between different
diseases. For example, although the ‘‘chemdependency’’ diseases
are obviously different from the neurological and psychological
diseases, some diseases in the ‘‘chemdependency’’ class, including
nicotine, dopamine and antisocial, not only relate to chemdepen-
dency but also to neurology and psychology. In the DMSPN, these
diseases were clustered into the neurological and psychological
cluster at the global level (Figure 5C). In addition, the high
correlations between metabolic subpathways also decreased the
clustering phenomenon of the DMSPN.
Correlations between network topology and genes
within disease-related metabolic subpathways
Many diseases, especially complex diseases, are usually related
to disruption of underlying functions in metabolic subpathways.
Most of the biological functions of a metabolic subpathway are
carried out by biochemical interactions between gene products
within subpathways. Therefore, involvement of a high proportion
of disease genes in a subpathway might increase the possibility of
disruption of the corresponding subpathway, finally leading to
more diseases. To examine this, we measured the ratio of the
number of disease genes to the number of total genes within each
subpathway of the DMSPN. We found that the ratio significantly
Figure 4. Evaluating the clustering phenomenon using BD and BH measures. (A) The plot of BD and BH of 18 disease classes. (B) The plot
of BD and BH of 11 metabolic subpathway classes.
doi:10.1371/journal.pone.0021131.g004
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16; Figure 6A). Moreover, there were on average 20 disease genes
in a disease-related subpathway, representing 36.3% of the total
genes in a subpathway. These suggested that subpathways
associated with more diseases tend to contain higher ratios of
disease genes. Similarly, metabolic subpathway regions with a high
ratio of disease genes also tend to cause more types of diseases due
to the high positive correlation between degree and disease
diversity of the subpathway node (see Figure S3).
The ratio of disease genes within a metabolic subpathway was
significantly associated with the number of diseases induced by
dysfunction of the corresponding subpathway. Other types of genes
within these disease risk regions could therefore also be significantly
associated with disease diversity of subpathways. To examine this,
we firstly tested essential genes, whose functions are necessary for
organisms to survive and reproduce. Essential genes are often
compared with disease genes in many studies. Some recent studies
have found that diseases genes and essential genes may encode hubs
in protein interaction network [42,43,44]. Other studies reported
only a weak correlation between disease genes and hubs [45].
Essential genes may have a direct association with cancer [12] and
may be regarded as the most severe ‘‘disease’’ genes [46]. Can the
disease-related functional differences between disease genes and
essential genes be observed in the subpathway regions of the
DMSPN? To address this question and test relationships between
essential genes and the topology of the DMSPN, we measured the
ratio of essential genes within each subpathway in the DMSPN.
2486 human essential genes were obtained according to the lethal
phenotype information of the corresponding mouse orthology (see
Materials and methods) from the Mouse Genome informatics
[47,48]. We then matched them to each subpathway for calculating
the ratio of essential genes of subpathways. Surprisingly, the
Figure 5. Hierarchical clustering on the DMSPN using the city-block distance and complete linkage method in the Cluster3 software
package and JavaTreeView imaging software. (A) Hierarchical clustering between 243 diseases and 302 metabolic subpathways. The
corresponding cell was colored orange if there was an edge between the disease and subpathway in the DMSPN. Disease labels and subpathway
labels were colored according to the disease class colors and subpathway class colors used in Figure 2 and 3. (B) Zoom-in plot of part of the pink
circled region in Figure 5A, showing the psychological, neurological, and chemdependency disease classes and amino acid metabolism subpathways.
(C) Zoom-in plot of part of the disease labels in the lower-right region of Figure 5A. (D) Zoom-in plot of part of the subpathway labels in the lower-
right region of Figure 5A.
doi:10.1371/journal.pone.0021131.g005
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total genes within each subpathway decreased significantly as the
degree of the corresponding subpathway increased (P-value,
2.2e–16) (Figure 6B), which was a significant negative correlation
between the ratio of essential genes and the degree of a subpathway.
The trend between essential genes and the topology of the DMSPN
was opposite to the trend between disease genes and the topology of
the DMSPN, suggesting that the DMSPN is able to distinguish well
the disease-related functional differences between disease genes and
essential genes. This result also indicated that regions of metabolic
pathways with a high ratio of essential genes were less likely to lead
to more types of diseases. Mutation of essential genes usually causes
severe functional impairment that tends to result in lethality. Thus,
abnormalities within a subpathway that contains a higher ratio of
essential genes might lead to lethality in patients before suffering
from more diseases whereas abnormality of the subpathway that
contains higher ratio of disease genes more easily make patients
survive or die after suffering from more and more diseases.
We further tested housekeeping (HK) genes and tissue-specific
genes (TS). HK genes are constitutively expressed in all tissues and
cell types to maintain basic cellular functions. Whereas, TS genes are
expressed at a much higher level in a single tissue than in others.
Expression regulation differences between HK and TS genes were
analyzed recently [49,50,51]. We downloaded the HK and TS gene
dataset used by She et al. [49] which contained 1522 human HK
genes and 975 TS genes identified from the gene expression profiles
of 42 normal human tissues using high-density microarrays and the
conservative identification criteria. We found that there were the
higher ratio of TS genes as a subpathway was associated with more
diseases (P-value,1.63e–13) (Figure 6D). However, there was no
significant correlation between the ratio of HK genes and the degree
of subpathways (P-value=0.01) (Figure 6C). Many studies have
shown that HK genes are less likely to mutate and are more
conserved than TS genes, that they are more stably expressed and
that they are more enriched in basic maintenance biological processes
of the cell. HK genes may thus play a basic role in the cell and
maintain stable numbers regardless of whether abnormalities of the
subpathway regions that contain these genes lead to more types of
diseases. However, TS genes show similar trends with disease genes,
for disease genes tend to be expressed specifically in some tissues. In
summary, the DMSPN is able to distinguish well the disease-related
functional difference between HK genes and TS genes.
Disease genes within the potential disease-related subpathways
of DMSPN may play key roles in regulating these subpathways.
Figure 6. Correlations between network topology and genes within disease-related metabolic subpathways. For each subpathway in
the DMSPN, the degree of the subpathway and the ratio of different types of genes within the subpathway were calculated. Gray ‘‘6’’ symbols
represent subpathways. Black horizontal lines are the average of the ratio of genes. Color points correspond to the binned ratio values and error bars
correspond to the standard deviations of the binned ratio values. The linear regression model was used to test the trends in correlations and the
significance of these trends was estimated. (A) The ratio of disease genes divided by all genes within the subpathways. (B) The ratio of essential
genes divided by all genes in the subpathways. (C) The ratio of housekeeping genes divided by all genes in the subpathways. (D) The ratio of tissue-
specific genes divided by all genes in the subpathways.
doi:10.1371/journal.pone.0021131.g006
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genes and degree of subpathways, disease genes should adopt
different regulation intensity and have different coexpression with
other types of genes at expression levels. To address this issue, we
computed coexpression between genes using expression data
from 36 different human tissue microarray experiments [52]. The
results showed that within subpathways, the median values for the
average coexpression between: disease genes and disease genes,
disease genes and essential genes, disease genes and HK genes,
disease genes and TS genes, disease genes and other genes, and
between all genes, were 0.24, 0.20, 0.17, 0.30, 0.15 and 0.15
respectively. As illustrated in Figure 7, disease genes within a
subpathway have higher average coexpression values than
expected by random (P-value,0.0007, Wilcoxon rank-sum test,
we used the average coexpression between all genes as a random
control). Moreover, disease genes showed higher coexpression
with essential genes compared with that expected by chance (P-
value,3.907e–05, Wilcoxon rank-sum test). However, coexpres-
sion between disease genes and HK genes did not show
significant differences compared with that expected by chance
(p-value=0.68). These results suggest that disease genes may
weakly influence HK genes, but significantly influence essential
genes. The different regulation intensities might explain the
differences of trend between the ratio of different types of genes
and the degree of subpathways. As a result, those genes intensely
influenced by disease genes might be closely associated with
disease diversity of subpathways. Taken together, these findings
indicated that the diversity of diseases caused by abnormalities in
a subpathway region might be significantly associated with
disease genes, essential genes and TS genes within the
corresponding subpathway. However, significant correlations
between HK genes and disease diversity of subpathways may
not exist.
Discussion
We constructed a disease–metabolic subpathway network using
the disease-gene associations and ‘‘k-clique’’ subpathway identifi-
cation method. We used the ‘‘k-clique’’ method to divide large
pathways into multiple subpathways. When k=3, the distance
amongall enzymeswithina subpathway was nogreaterthan 3.This
ensured that the identified disease risk subpathways were located in
the disease-related local regions of pathways, and also increased the
tendency for genes in a subpathway to share similar biological
functions and be involved in similar biological processes. To date,
most pathway identification methods have only identified disease-
related entire pathways without considering the scale of these
pathways. However, each pathway has the obviously different
scales. These differences in scale hinder the evaluation of disease-
related pathways from global networks and the identification of
disease-related high risk subpathways that are usually located in the
local regions of pathways. Through employing the subpathway
identification method, we were able to ensure that each subpathway
was represented on a small scale. Moreover, the identified
subpathways could be located within the disease risk regions of
these pathways. By applying this methodology to all diseases, we
were finally able to investigate global relationships between diseases
and their corresponding regions of pathways.
Through our analyses of the DMSPN based on network
biology, we found that the degree distribution of subpathway
nodes of the actual DMSPN was significantly broader than that
of random networks. A few subpathways were significantly linked
to many diseases. However, most of these metabolic subpathways
with high degrees belonged to fundamental metabolism path-
ways, suggesting that abnormalities in fundamental meta-
bolism processes may cause more types of diseases. To test the
clustering phenomenon of diseases and metabolic subpathways, we
Figure 7. The average coexpression of gene pairs within the disease-related metabolic subpathways.
doi:10.1371/journal.pone.0021131.g007
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subpathway class information from the GAD and KEGG
databases. We also performed hierarchical clustering on the
DMSPN without considering disease class information. The results
showed that disease and subpathway classes displayed the slight
clustering. For many classes, members within them still main-
tained many links with members of other classes although there
were more links between members within the class. Therefore,
diseases in the same disease class tended to form many small
clusters instead of individual large clusters. Furthermore, we tested
correlations between network topology and genes within disease-
related metabolic subpathways. We found that the ratio of disease
genes and the ratio of tissue-specific genes in a subpathway
significantly increased as the degree of the subpathway increasesd.
However, the ratio of essential genes significantly reduces and the
ratio of housekeeping genes remained relatively unchanged.
Furthermore, the coexpression levels between disease genes and
other types of genes were calculated for each subpathway in the
DMSPN. The results indicated that those genes intensely
influenced by disease genes, including essential genes and tissue-
specific genes, might be significantly associated with the disease
diversity of subpathways. Taken together, these results provided
strong support for the functional importance of the DMSPN.
To confirm the validity of our results, we also constructed the
DMSPN with k=4 and repeated the analyses. We find that the
results reported in this paper were similar to the results of the
DMSPN with k=4 (see Text S1, Figure S4 and S5). We also noted
that the completeness of the DMSPN is limited by the
completeness of metabolic pathway data, disease–gene associa-
tions, and the false positive results obtained by enrichment analysis
method. Improvements in the quality of this input data will
provide a more accurate and robust DMSPN. Although these data
sets and methodology are far from complete, our network analyses
still provide statistically significant characteristics of the relation-
ships between diseases and metabolic subpathways.
Materials and Methods
The Genetic Association Database (GAD)
To predict disease–metabolic subpathway associations, we first
obtained disease–gene associations from the GAD. The GAD is
the NIH-supported public repository for human genetic associa-
tion studies of complex diseases, which contains the complete
known gene–phenotype associations and include non-Mendelian
common complex diseases [24]. We downloaded all gene-
phenotype relationships (N=39910) in the GAD (December 15,
2008) and processed this data by merging redundant terms (e.g.,
112 ‘‘alcohol abuse’’ terms were merged). The detailed method-
ology used for processing this data was provided in Text S1.
Finally, we obtained 15149 unique gene–disease relationships
from 39910 primary terms. These associations were composed of
412 diseases and 2832 disease genes (see Dataset S2). We can also
obtain the information of disease classes from the GAD. In
particular, each disease corresponds to a disease class and in total
412 diseases belonged to 18 disease classes.
Essential genes
To obtain human essential genes, we used the phenotype
information of the corresponding mouse orthology. If a mouse
suffered from the lethality when a particular gene was knocked
out, a human ortholog of this gene was defined as an essential
gene. This type of methodology has been widely applied to obtain
information on human essential genes [12,13]. Both human–
mouse orthology data and mouse phenotype data were obtained
from the Mouse Genome informatics [47,48] (August 6, 2009). For
the phenotype data, the embryonic, prenatal and postnatal
lethality were treated as lethal phenotypes. Finally, 2486 mouse-
lethal human orthologs were classified as human essential genes.
Housekeeping (HK) genes and tissue-specific (TS) genes
HK genes are constitutively expressed in all tissues to maintain
cellular functions, while TS genes are expressed at a much higher
level in a single tissue than in others. Expression regulation
differences between HK and TS genes were analyzed recently by
She et al. [49]. We downloaded the HK and TS genes dataset
which was used in that paper. The dataset contains 1522 HK
genes and 975 TS genes, which were identified from the gene
expression profiles of 42 normal human tissues using high-density
microarrays and the conservative identification criteria [49].
Computation of BD and BH
Park et al. developed D and H measures to capture the detailed
interplay between the network structure and node properties when
nodes in a network belong to two distinct classes [53]. These
measures have been successfully applied to the modularity
evaluation of protein–protein interaction networks [53] and
disease networks [38]. In this study, we revised the D and H
measures for one-mode networks (e.g., protein–protein interaction
networks) to BD and BH measures for bipartite networks, such as
the disease–metabolic subpathway network (see Text S1). For
diseases in each disease class in the DMSPN, BD and BH were
calculated and finally 18 pairs of (BD, BH) values are shown in
Figure 4A. BD.1 (BD,1) indicate that diseases in the disease
class tend to connect more (less) densely among themselves than
expected by chance. Similarly, BH.1 (BH,1) means that diseases
in the disease class have more (fewer) connections to diseases in
other classes than the random expectation. If BD.BH, diseases in
the disease class tend to display a clustering phenomenon in the
DMSPN. If BD.1 and BH,1, diseases in the disease class tend to
display a clear clustering phenomenon in the DMSPN. Similarly,
we are also able to calculate the BD and BH values of subpathways
in a subpathway class (Figure 4B).
Supporting Information
Figure S1 Screenshot of using the subpathway identifica-
tion method provided in the SubpathwayMiner package to
construct the disease–metabolic subpathway network.
After installing the SubpathwayMiner package in R, we can use
the generateNetwork function to construct the disease–metabolic
subpathway network with the different distance parameter k.
(TIF)
Figure S2 The basic network features of the DMSPN. (A)
The degree distribution of subpathway nodes of the actual DMSPN
was significantly broader than that of random networks (P-value,10e-
10). (B) The degree distribution of disease node did not display such
highly significant difference (P-value=0.02). (C) The edges in the
DMSPN were significantly denser than expected by chance (P-
value,0.001). (D) The size of giant component of the DMSPN was
significantly smaller than expected by chance (P-value,0.001).
(TIF)
Figure S3 Correlation between the disease diversity
and the degree within disease-related metabolic sub-
pathways. For each subpathway in the DMSPN, the degree of
subpathway and the disease diversity were calculated. Gray ‘‘6’’
symbols represented subpathways. Black horizontal lines are the
average of value of disease diversity. Color points correspond to
Disease-Metabolic Subpathway Network
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deviations of the binned ratio values. The linear regression model
was used to test the trends in correlations and the significance of
these trends was estimated. The result showed that there was a
significant positive correlation between the disease diversity and
the degree of a subpathway (P-value,2.2e–16).
(TIF)
Figure S4 Correlations between network topology and
genes within disease-related metabolic subpathways.
For each subpathway in the DMSPN with k=4, the degree of
subpathway and the ratio of different types of genes within
subpathway were calculated. Gray ‘‘6’’ symbols represented
subpathways. Black horizontal lines are the average of the ratio of
genes. Color points correspond to the binned ratio values and
error bars correspond to the standard deviations of the binned
ratio values. The linear regression model was used to test the
trends in correlations and the significance of these trends was
estimated. (A) The ratio of disease genes divided by all genes
within the subpathways. (B) The ratio of essential genes divided by
all genes in the subpathways. (C) The ratio of housekeeping genes
divided by all genes in the subpathways. (D) The ratio of tissue-
specific genes divided by all genes in subpathways.
(TIF)
Figure S5 The average coexpression of gene pairs
within disease-related metabolic subpathways in the
DMSPN with k=4.
(TIF)
Dataset S1 Examples of merging broad phenotypes.
(XLS)
Dataset S2 The curated gene–disease associations from
the GAD.
(XLS)
Dataset S3 The disease-metabolic subpathway associa-
tions.
(XLS)
Text S1 Supplementary information text.
(DOC)
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